Discussion  by unknown
TABLE 4. Patients taking clopidogrel who experienced postoperative bleeding, myocardial events, or operative mortality
Patient Procedure Taking aspirin Coronary stent Postop morbidity Operative mortality Reoperation for bleeding
1 Ivor Lewis No Yes Pulmonary embolism Yes No
2 Lobectomy Yes Yes Postop bleeding No Yes
3 Wedge Yes No Postop bleeding No Yes
4 Ivor Lewis Yes Yes Myocardial infarction No No
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S who have a coronary artery stent as their indication for anti-
platelet therapy. However, in those patients who are to un-
dergo a redo thoracotomy and who receive both
clopidogrel and aspirin, there is an increased risk of bleeding
secondary to the takedown of adhesions. It may be best in
these patients to stop their aspirin and have them continue
their clopidogrel alone. Further studies are needed.
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Dr David Park Mason (Cleveland, Ohio). I have no disclo-
sures. Dr Cerfolio, I enjoyed the talk and I enjoyed your paper
very much.
I do not think that it can be overstated that clopidogrel is a potent
inhibitor of coagulation, but also that you had excellent results, I
think, because you did excellent surgery and cautious surgery,
and not everyone is you. We have to think a little bit about the gen-
eralizability of the results. Careful and cautious surgery is obvi-
ously what you did, and the results are outstanding.
More and more patients are on a clopidogrel regimen, and many
for different reasons, when they are referred to us. Twenty-one of
your 33 patients were on it for coronary stents, and I think these
are the ones we worry about most. The others were on it for a smat-
tering of other reasons, such as peripheral vascular disease, for which
we do not worry as much. My question is, should we treat all clopi-
dogrel-treated patients the same? Are there some patients in whom it
would not be so worrisome to consider stopping clopidogrel?
Dr Cerfolio. I think if you have a patient who has been pre-
scribed clopidogrel because he had a clot in his toenail in 1972,
which we see all the time, and there is no reason why he is on it
and it’s a redo, I would take the patient off and decrease my risk,
However, if the patient is on it for a good reason, such as a recently
deployed stent with significant coronary artery disease, especially
a drug-eluting stent, I would keep him on it but stop the aspirin if
the operation was a redo. If it was a primary thoracotomy, I would
continue both.
DrMason.My second question has to do with the heterogeneity
of your population. You did many different cases, and for that rea-
son you actually gained a lot of experience in operating on these pa-
tients who were receiving clopidogrel. You mentioned that the only
operations you would hesitate to perform in the future are the redo
thoracotomies. Are there any other operations that you would say, I
do not think that’s a good idea. I saw this. I learned something from
this that I would recommend to my surgeons in the future.
Dr Cerfolio. That is a great question. I would counter your first
part by saying that if I can do it, everybody in this room can do it,
because I am probably not going as slowly as I should. In doing the
redo, the surgeon really has to slow down and take those adhesions
down quickly. You cannot put your hand in there and tear stuff.
You have to use the Bovie device. But I think mediastinoscopy
was what I worried about the most. I had to use Surgicel hemostats
(Ethicon, Inc, Somerville, NJ) on a couple of those patients. They
did not bleed or need transfusions, but I think you need to be very
careful with that. If you are going to do a mediastinoscopy, just
make sure that the patient needs to be on the clopidogrel regimen.
I do still think it is safe.
Dr Sandro Mattioli (Bologna, Italy). That is an interesting
issue. In Italy we have launched a multicenter study with 7 veryery c November 2010
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ford this only on an observational basis. The point is that we do not
know how frequent this problem is. I do not understand your re-
cruitment. Did you get your patients with and without double med-
ical therapy in sequence or were they historical cases? So the first
question is frequency, because if this is frequent, we can talk to
the cardiologists; otherwise, they will ignore us.
Dr Cerfolio. This is a consecutive series. Once we said we were
going to follow this program, we applied it to everyone who was
referred to us. By contrast, in the patients whom we treated earlier,
I was stopping clopidogrel because I did not think I could operate
on them while they were receiving it.
Dr Joseph B. Shrager (Stanford, Calif). Rob, the data are not
very granular. It is back to the operating room or not back to the op-
erating room or transfusion or no transfusion. Do you have no chest
tube output data?Maybe if you got a little more granular you would
see differences.
Dr Cerfolio.Yes, we do. That information is in the paper. How-
ever, these patients bled significantly intraoperatively and postop-
eratively. One patient lost 1000 mL and I think the other lost
1400 mL.
Dr David J. Sugarbaker (Boston, Mass). Given the degree of
equipoise as to whether or not you should leave them on their clo-
pidogrel and operate or take them off their clopidogrel and run the
risk of having a coronary event, did you consider a prospective
randomized trial following an IRB approach?
Dr Cerfolio. No, because I wanted to show safety first. This
would be the benchmark to go to that trial.
Dr Sugarbaker. I see. It does not seem like it would have
enough power to draw any conclusions regarding safety, but I
will defer to the statisticians.
Dr Bryan F. Meyers (St Louis, Mo). I think this is a useful and
practical study and I thank you for doing it.
If you look at retrospective case series, when people had stopped
the clopidogrel in patients with stents and operated on them, what
you learn is that there is a 10% myocardial infarction rate, and
among those that have an infarction, there is about a 50% death
rate. This is a substantial problem in that group of patients. I would
like to point out an interesting thing that came out talking to our car-
diologists. The reason that the 6-month number exists—when they
talk about using clopidogrel for 6 months—is that in some of the
early stent trials, the company that makes clopidogrel offered 6
months of free clopidogrel. The end point of that time is not evi-
dence-based at all, so you might as well just keep continuing it.
Did you limit this to just patients who had had stents within 6
months?
Dr Cerfolio. No, we did a consecutive series of patients who
came to us on a clopidogrel rgimen and operated on them.
DrMeyers.You operated on anybody on clopidogrel regardless
of how long it was before their cardiac intervention?
Dr Cerfolio. Yes, sir.
Dr Meyers. That’s good.
Dr Scott I. Reznik (Temple, Tex). Inasmuch as the American
Association of Anesthesiologists will prevent placement of an epi-
dural with recent clopidogrel use, did you see any more respiratory
embarrassment or more atelectasis or even more pain?
Dr Cerfolio. Good question. None of these patients got an epi-
dural because I certainly did not want to have that conversation.The Journal of Thoracic and CaThey all got an on-Q pain pump, and we did not notice the differ-
ence, but, again, it was a small number of patients.
Dr Ayman Abdul-Ghani (Anniston, Ala). I enjoyed your talk,
Dr Cerfolio.
Back when I used to do cardiac surgery in Liverpool, I tried to do
a study on taking down the mammary while the patient was receiv-
ing clopidogrel. We had to stop it after 10 or 15 cases, not because
of take-back for bleeding but because of chest tube output. We used
to transfuse that amount back into the patient. Have you considered
putting the patients on a regimen of enoxaparin sodium (Lovenox)?
I have done it on 1 or 2 patients, stopping the clopidogrel, using
enoxaparin sodium at home, with the approval of the cardiologist,
stopping it before surgery, and starting clopidogrel immediately af-
ter surgery.
Dr Cerfolio. That is one of the compromises that we were doing
in the past, but it is still a compromise. The anesthesia and cardiol-
ogy data are very clear. If you stop that clopidogrel, you are risking
a lawsuit with much higher risk of perioperative myocardial infarc-
tion. So I do not think that is the solution. That is not going to make
people happy. And the cost of enoxaparin sodium at home is
through the roof. You could do that, but I do not think that is
a good solution.
Dr Daniel C. Wiener (Boston, Mass). There is some literature
indicating that about 20% of patients are nonresponders to clopi-
dogrel. I wonder whether, in that small number, some of the results
are skewed by the fact that some of those patients may actually be
nonresponders, and how can that be addressed?
Dr Cerfolio. That is a great question and one that we cannot an-
swer. Some of these patients did not seem to bleed any more than
patients who were not receiving clopidogrel. That may be right,
but I cannot answer that.
Dr Gunda Leschber (Berlin, Germany). I think you mentioned
that you did a decortication as well on clopidogrel. Could you com-
ment on this?
Dr Cerfolio. Yes. That really was risky. That was done on a pa-
tient in the hospital whomwe took and did that the next day.We did
okay, but we were doing a pleurectomy, a visceral pleurectomy,
and I usually do a parietal pleurectomy. We went slowly and we
were smart and did okay.
Dr Shrager. You had IRB approval to do this?
Dr Cerfolio.We had to inform the IRB just that we were going
to try this to start.
Dr Shrager. You had IRB approval?
Dr Cerfolio.Yes.We just told the IRBwe were going to do this.
Dr Shrager. Did they say you were exempted from whatever?
Dr Cerfolio. No, no. They did not say we had to do anything
fancy. They did not say that we needed to go through committees
or boards. We went to anesthesia, went to cardiology, told the
IRB we were going to try to operate on clopidogrel, and we got
it in as just the safety trial.
Dr Sugarbaker. So you did not have to do an informed consent?
Dr Cerfolio. Yes, we had to do an informed consent, but we did
an expedited thing. We did not need to go through the typical IRB
that takes us forever.
Dr Shekar Reddy (Durham, NC). It was rather surprising to
hear that your patients did not bleed at all, and that ties in with
the previous question about the nonresponders. In your future
work, if you add a thromboelastogram to these patients asrdiovascular Surgery c Volume 140, Number 5 975
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data to prove that they have been on antiplatelets and the extent to
which those drugs have been useful. If you can tie that in with your
outputs, I think you will have a much more robust experimental
design in the future.976 The Journal of Thoracic and Cardiovascular SurgDr Cerfolio. As a scientist that is good, but as a clinician, if the
patients do not bleed, I am thrilled. I do not care why they are not
bleeding; they ain’t bleeding. For me, the idea that all 33 were not
responders is unlikely. I take your comment, but I want you to listen
to my response.ery c November 2010
